Goldman Sachs Predicts Gold Prices To Surge To $3,700 By Late 2025

by News Editor

April 15, 2025

In a bold forecast, Goldman Sachs has increased its gold price prediction to $3,700 per ounce by the end of 2025. This adjustment comes amid unexpected demand from central banks and a strengthening perception of recession risks, drawing investors towards gold ETFs.

Key Points

Initial forecasts pegged the price at $3,300, but central banks’ monthly gold acquisitions, averaging 80 tons — much higher than the 17-ton average before 2022 — have warranted a forecast revision.
Gold prices have already seen a significant increase of over 23% in 2025, surpassing the $3,200 mark for the first time.
Should central banks continue acquiring at an accelerated pace, or if a recession prompts a capital influx into ETFs, gold could rise to $3,880 within this year.

What To Watch

Economists estimate a 45% chance of a U.S. recession within 12 months, potentially redirecting capital to gold ETFs. Should central banks ramp up purchases to 100 tons monthly, or recession-driven demand persist, gold might reach $3,880 by year-end. Alternatively, if economies show resilience and political uncertainty lessens, gold prices could stabilize around $3,550.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The Future Forbes Realty Global Properties

Anthropic Acquires Coefficient Bio In $400 Million Stock Deal

by THEFUTURE.TEAM

April 6, 2026

Anthropic acquired biotech AI startup Coefficient Bio in a deal valued at approximately $400 million in stock, according to people familiar with the matter. Sources confirmed the transaction, although detailed financial terms were not publicly disclosed.

Deepening Forays Into Healthcare And Life Sciences

The acquisition follows Anthropic’s earlier launch of Claude for Life Sciences, a tool designed to support scientific research and drug discovery. The deal expands the company’s activity in healthcare and biotechnology. Anthropic is increasing its focus on applying AI models to scientific workflows, including data analysis and experimental design. Expansion into life sciences reflects broader industry trends.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Transforming Computational Drug Discovery

Coefficient Bio was founded eight months ago by Samuel Stanton and Nathan C. Frey, both former researchers at Genentech’s Prescient Design group. The company focused on applying AI to drug discovery and biological research processes. Its technology aims to improve efficiency in identifying drug candidates and analyzing biological data. Early-stage development reflects growing interest in AI-driven research tools.

Strategic Talent And Expertise Integration

Around 10 employees from Coefficient Bio will join Anthropic following the acquisition, strengthening its health and life sciences team. The group will contribute to the development of AI models for scientific and medical applications. Access to specialized talent supports the expansion of capabilities in drug discovery and biological research.

Industry Context And Outlook

Investment in AI for drug discovery has increased as companies seek to reduce development timelines and costs. Large technology firms and startups are expanding activity in this area. Further developments will depend on how effectively Anthropic integrates the team and advances its life sciences strategy.

Breaking news